BCR/ABL-positive acute myeloid leukemia (AML) is a rare disease, characterized by a poor prognosis, with resistance to induction chemotherapy and frequent relapses in responsive patients. Here we report a case of BCR/ABL-positive AML-M6 who, after relapse, was treated with Imatinib Mesylate (600 mg/
Long-term remission in a patient with BCR/ABL-positive acute myeloid leukaemia on maintenance therapy with imatinib
โ Scribed by Enrico Schalk; Silke Neum; Sandra Kranz; Katrin Scheinpflug; Martin Mohren
- Publisher
- Elsevier Science
- Year
- 2009
- Tongue
- English
- Weight
- 190 KB
- Volume
- 33
- Category
- Article
- ISSN
- 0145-2126
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75-90% of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage of patients achieve complete molecular response (CMR). Very little is known about IM discontinuation. We report the case o
## Background: In 1982, the fourth international workshop on chromosomes in leukemia reviewed data prospectively collected on 716 patients with acute myeloid leukemia (aml) diagnosed between 1980 and 1982. the present study examined the extended follow-up on these patients. ## Methods: The analys